News
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback